Boundless Bio has announced a strategic portfolio prioritization aimed at optimizing its oncology programs, particularly focusing on the combination therapy of BBI-355 and BBI-825, alongside a new ...
SAN DIEGO, May 23, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to ...
Highest priority programs – BEAM-101 and ESCAPE for sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency – expected to provide foundation for meaningful value creation Company to ...
Genmab to discontinue clinical development of acasunlimab following a portfolio review Decision reflects prioritization of higher‑impact opportunities across Genmab’s late‑stage pipeline and ...
I would like to convey my gratitude for their innumerable contributions to Turnstone, their commitment to patients with solid tumors, and I wish them the very best in their future endeavors.” The ...
Givastomig: a Claudin 18.2 ("CLDN18.2") x 4-1BB bispecific antibody, will be the lead clinical program following the Company's portfolio prioritization The Company has completed enrollment of a dose ...
- The Company will focus resources on advancing its lead asset, PYX-201 - PYX-201 is a novel first-in-concept antibody-drug conjugate (ADC) where significant RECIST responses were seen in head and ...
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced a re-alignment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback